论文部分内容阅读
目的:探究瑞替普酶及尿激酶静脉溶栓治疗急性心肌梗死的临床疗效。方法:选取2014年3月~2015年3月收治的60例急性心肌梗死后患者,随机分为30例观察组和30例对照组,对照组使用尿激酶静脉溶栓治疗,观察组使用瑞替普酶治疗,两组治疗的时间均为30d,观察并记录两组患者治疗后的临床效果。结果:观察组患者6 h和12 h内的冠脉再通成功率分别为80.0%(24例)和93.3%(28例),对照组患者6 h和12 h内的冠脉再通成功率分别为60.0%(18例)和70.0%(21例);观察组患者3例合并出血,发生率为10.0%,对照组患者8例合并出血,发生率为26.6%,组间差异明显,具有统计学意义(P<0.05)。结论:对急性心肌梗死患者使用瑞替普酶治疗,治疗效果明显,副反应少,延缓了病情发展,值得在临床上推广使用。
Objective: To investigate the clinical efficacy of reteplase and urokinase intravenous thrombolysis in the treatment of acute myocardial infarction. Methods: Sixty patients with acute myocardial infarction who were admitted from March 2014 to March 2015 were randomly divided into observation group (30 cases) and control group (30 cases). The control group was treated with intravenous thrombolytic therapy of urokinase. The observation group The enzyme treatment, the two groups were treated for 30 days, observe and record the clinical effect of the two groups after treatment. Results: The success rate of coronary recanalization within 6 h and 12 h in the observation group was 80.0% (24 cases) and 93.3% (28 cases) respectively. In the control group, the success rate of coronary recanalization within 6 h and 12 h Respectively, 60.0% (18 cases) and 70.0% (21 cases) respectively. In the observation group, 3 patients had combined hemorrhage with a rate of 10.0%, and 8 patients in the control group had bleeding with a rate of 26.6% Statistical significance (P <0.05). Conclusion: The use of reteplase in patients with acute myocardial infarction, the treatment effect is obvious, fewer side effects, delay the progression of the disease, it is worth promoting in clinical use.